Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules in combination with liposomal doxorubicin (PLD) in patients with advanced solid tumours (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134498/
https://www.ncbi.nlm.nih.gov/pubmed/25025963
http://dx.doi.org/10.1038/bjc.2014.345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134498/
https://www.ncbi.nlm.nih.gov/pubmed/25025963
http://dx.doi.org/10.1038/bjc.2014.345

Ejemplares similares